ESR1 and breast carcinoma: In preclinical studies, the SERCA H3B-6545 had consistent activity against endocrine-therapy-resistant tumors expressing wild-type or mutant ESR1 transcripts [237], stimulating its testing into an ongoing clinical trial on breast cancer patients (NCT03250676).